Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦

Cardiologist, Associate Prof. of Internal Medicine, Rio de Janeiro State University. Passion for preventive Cardiology, heart failure, art and classical music

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

@Hragy @mmamas1973 @hvanspall Oh, I missed your birthay, hope I'm still within the 95% CI intervals to wish you a happy (though belated) birthday!

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

@Hragy I guess so!

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

@drpablocorral @fastquant0 @society_eas @skathire @Drlipid 🙏🙏🙏🙏🙏🙏🙏

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

Research on base editing for PCSK9 is moving forward with impressive results. A single infusion of Verve-102 base editor leads to a sustained, up to 60% lowering of LDLc (and > 80% of PCSK9) overtime👏👏 #EASCongress2026 @society_eas @skathire @drpablocorral @Drlipid

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

@drpablocorral @fastquant0 @society_eas @skathire @Drlipid Depends, Pablo...For me... Waiting 10 years to witness this advance laying ground in clinical practice, may be quite a long and uncertain time...😄

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

Full publication available at https://t.co/jlXkfBHpL4
#Prevention #Inflammation #Cardiovascular #Atherosclerosis @azinkh96 @niharika_reddy9 @drpablocorral @SABOURETCardio @MeralKayikcoglu @LaleTokgozoglu @Drlipid @fotisbarkas @FedericaFogacci

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

#EASCongress2026 A new actionable pathway is tested in a phase 1 study by @ProfKausikRay and collaborators. Rivonoplast, a potent inhibitor of NLRP3 inflamassome led to early and sustained reversible sCRP reduction compared to placebo. (Follow next tweet👇👇)

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

#EASCongress2026
@AndreZimerman presents a late breaker clinical trial exploring olezarsen for acute pancreatitins in pts w/triglycerides>10 mMol/L. As can be seen, a stark difference in favour of Olezarsen in this cohort highly exposed to risk of acute pancreatitis.

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

Thread #3 Looking forward to learning more about this actionable therapeutic pathway! #EASCongress2026 #Cardiovascular #Inflammation #Atherosclerosis #Prevention #CardioX @Drlipid @biljana_parapid @MutazAlsabah @MaximaMendez15 @cherskams @azinkh96 @niharika_reddy9

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

Thread #1 This afternoon, there will be an unmissable late-breaker presentation by @ProfKausikRay, at Aravanis Hall, exploring NLRP3 inflamassome inibition in humans with inflammatory residual risk for ASCVD, as depicted below (Read following tweet for additional information)

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

Thread # 2 Ruvonoplast is a pro-drug that crosses the blood-brain barrier and is converted intracellularly into its active metabolite (Also yielding potential benefits for treatment of neurological diseases such as LAS, Parkinson and even Alzheimer). 👇👇

[European Atherosclerosis Society @society_eas]

Atherosclerotic cardiovascular disease (ASCVD) remains the world’s leading cause of death, despite major advances in lipid testing and treatment. Many patients with familial hypercholesterolaemia (FH), elevated lipoprotein(a), severe hypertriglyceridaemia, and other complex lipid disorders still lack access to specialized care and evidence-based therapies.

This consensus paper from the EAS Lipid Clinic Network provides practical recommendations on how lipid clinics can be organized and strengthened worldwide. It covers education, staffing, patient pathways, registries, and healthcare policy to improve prevention and reduce long-term healthcare costs.

New therapies and diagnostic tools are rapidly emerging, while cardiovascular disease continues to place a major burden on healthcare systems. A 2024 EAS Lipid Clinic Network survey also revealed major inequalities in access to lipid clinics and treatment implementation across countries.

The EAS is a global leader in lipid research, education, and guideline development. Through its international Lipid Clinic Network, the Society brings together experts, healthcare professionals, and patient representatives to deliver practical, evidence-based recommendations for real-world care.

Read the full publication: https://t.co/nOQLzsUVxg
To the press release: https://t.co/qVyuIKv9g9
To the key messages: https://t.co/M7US7ZMzc7

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

@williedunnam @society_eas @skathire @drpablocorral @Drlipid ApoB is the best predictor of ASCVD risk but its measurement usually comes out of the patient's pocket. Since there's a fairly good correlation w/ non-HDL cholesterol, we use it instead. Lp(a) is highly atherogenic "per particle" but largely outnumbered by LDL particles.

[Dr Meral Kayikcioglu @MeralKayikcoglu]

Our new EAS consensus statement published in #Atherosclerosis- Lipid clinics worldwide: harmonization & guidance on how to optimally organize & fund. A global effort of 55 countries >500 lipid clinics to improve lipid care, prevention, organization #EASCongress2026 @KatiOorni

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

@Drlipid @society_eas @skathire @drpablocorral Maybe more data from NEJM publication siultaneously released, but it's paywalled.

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

@Drlipid @society_eas @skathire @drpablocorral As far as I can recall, there were no comments about Lp(a)

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

👆🏽👆🏽 @SABOURETCardio @drpablocorral @Drlipid @LipidLover1030 @maciejbanach @CBallantyneMD @fikkumamoto @jamus_marcelo @Hragy

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

Pooled results from CoralReef lipids and HeFH studies presented today by @AL_Catapano: Enlicitide led to a safe apoB ⬇️ overtime, up to 50% at 24 wks, almost 50% at 52 wks. Over 80% of pts attained apoB goals @society_eas #EASCongress2026
#prevention #pcsk9 #lipids #cholesterol

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

At #EASCongress2026 a splendid conference by 2026 Anitschkov prize winner Heribert Schunkert on genetic and environmental interactions upon ASCVD. #genetics #GWAS #Prevention. For a deeper dive, read his most recent review: NEJM DOI: 10.1056/NEJMra2405153. @society_eas